{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:17:26Z","timestamp":1780406246820,"version":"3.54.1"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"38","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,19]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Neoadjuvant therapy (NAT)\u2019s potential impact on the long-term overall survival of patients with resectable pancreatic cancer (RPC) remains uncertain. This study aims to evaluate the efficacy and safety of NAT compared with upfront surgery (US) in patients with RPC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>From January 1, 2009 to October 1, 2024, we comprehensively searched PubMed, EMBASE, Web of Science, and Cochrane Library databases to identify randomized controlled trials comparing NAT with US for RPC. The primary outcomes were the relative risk (RR) of R0 resection rates (defined as negative surgical margins \u22641\u2009mm in postoperative pathology) and major complications (including pancreatic fistula, biliary fistula, gastroparesis, hemorrhage, intra-abdominal infection, etc). Additionally, we extracted and reconstructed patient-level survival data from Kaplan\u2013Meier curves to analyze the hazard ratio of median survival time between groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 6 randomized controlled trials involving 670 patients were included. NAT significantly improved the R0 resection rate compared with US (RR\u2005=\u20051.41, <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u2005=\u20050%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.00001). Four studies reported major postoperative complications, showing a trend toward reduced incidence with NAT (RR\u2005=\u20050.82, <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u2005=\u200559%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.54), though heterogeneity was high and results were not statistically significant. Survival data from 5 studies (median survival or Kaplan\u2013Meier curves) were reconstructed, revealing no significant difference in median survival time (hazard ratio\u2005=\u20050.91, <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u2005=\u200547%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.55).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>For resectable pancreatic ductal adenocarcinoma, NAT achieves higher R0 resection rates and reduces major postoperative complications but does not improve survival compared with US.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000044570","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:03:25Z","timestamp":1758575005000},"page":"e44570","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of efficacy and safety between neoadjuvant therapy and surgical treatment for resectable pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1097","volume":"104","author":[{"given":"Haojian","family":"Zuo","sequence":"first","affiliation":[{"name":"Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, China"},{"name":"The Second Clinical Medical College of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Chen","sequence":"additional","affiliation":[{"name":"Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"Li","sequence":"additional","affiliation":[{"name":"Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinpeng","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2104-8722","authenticated-orcid":false,"given":"Xiaoyong","family":"Luo","sequence":"additional","affiliation":[{"name":"Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, China"},{"name":"Department of Radiotherapy, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250928","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20250928","first-page":"17","article-title":"Cancer statistics, 2023.","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R3-20250928","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","article-title":"Therapeutic developments in pancreatic cancer: current and future perspectives.","volume":"15","author":"Neoptolemos","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R4-20250928","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology.","volume":"19","author":"Tempero","year":"2021","journal-title":"J Nati Compr Cancer Netw"},{"key":"R5-20250928","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.pan.2020.01.012","article-title":"Pancreatic cancer incidence and survival and the role of specialist centres in resection rates in England, 2000 to 2014: a population-based study.","volume":"20","author":"Exarchakou","year":"2020","journal-title":"Pancreatology"},{"key":"R6-20250928","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"R7-20250928","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1245\/s10434-013-2886-9","article-title":"Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.","volume":"20","author":"Katz","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"R8-20250928","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrae087","article-title":"Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: reconstructed patient-level meta-analysis of randomized clinical trials.","volume":"8","author":"Aliseda","year":"2024","journal-title":"BJS Open"},{"key":"R9-20250928","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial.","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"key":"R10-20250928","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41571-022-00612-6","article-title":"The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain.","volume":"19","author":"Springfeld","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"R11-20250928","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer.","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"R12-20250928","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s11605-015-2890-4","article-title":"Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets.","volume":"19","author":"Casadei","year":"2015","journal-title":"J Gastrointest Surg"},{"key":"R13-20250928","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S2468-1253(18)30081-5","article-title":"Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2\u20133 trial.","volume":"3","author":"Reni","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R14-20250928","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R15-20250928","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1245\/s10434-009-0416-6","article-title":"Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement.","volume":"16","author":"Evans","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"R16-20250928","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1245\/s10434-009-0408-6","article-title":"Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement.","volume":"16","author":"Callery","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"R17-20250928","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1245\/s10434-009-0413-9","article-title":"Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement.","volume":"16","author":"Abrams","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"R18-20250928","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00066-014-0737-7","article-title":"Neoadjuvant chemoradiation therapy with gemcitabine\/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.","volume":"191","author":"Golcher","year":"2015","journal-title":"Strahlenther Onkol"},{"key":"R19-20250928","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","article-title":"Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.","volume":"9","author":"Labori","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R20-20250928","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.annonc.2022.09.161","article-title":"Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX) \u2013 a randomized phase II trial of the AIO pancreatic cancer group.","volume":"34","author":"Seufferlein","year":"2023","journal-title":"Ann Oncol"},{"key":"R21-20250928","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement.","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"key":"R22-20250928","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R23-20250928","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves.","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"R24-20250928","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis.","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"R25-20250928","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"R26-20250928","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments.","volume":"12","author":"McGuinness","year":"2020","journal-title":"Res Synth Methods"},{"key":"R27-20250928","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"R28-20250928","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"R29-20250928","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"R30-20250928","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkac047","article-title":"Real-world cost-effectiveness of first-line gemcitabine plus nab-paclitaxel vs FOLFIRINOX in patients with advanced pancreatic cancer.","volume":"6","author":"Arciero","year":"2022","journal-title":"JNCI Cancer Spectr"},{"key":"R31-20250928","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1016\/j.vaccine.2015.05.105","article-title":"In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment.","volume":"33","author":"Vanpouille-Box","year":"2015","journal-title":"Vaccine"},{"key":"R32-20250928","doi-asserted-by":"crossref","first-page":"zqad011","DOI":"10.1093\/function\/zqad011","article-title":"Refining the treatment of pancreatic cancer from big data to improved individual survival.","volume":"4","author":"Bailey","year":"2023","journal-title":"Function (Oxf)"},{"key":"R33-20250928","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/SLA.0000000000002432","article-title":"Prognostic value of resection margin involvement after pancreaticoduodenectomy for ductal adenocarcinoma: updates from a French prospective multicenter study.","volume":"266","author":"Delpero","year":"2017","journal-title":"Ann Surg"},{"key":"R34-20250928","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/cam4.1071","article-title":"Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies.","volume":"6","author":"Zhan","year":"2017","journal-title":"Cancer Med"},{"key":"R35-20250928","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R36-20250928","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jamaoncol.2018.0329","article-title":"Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial.","volume":"4","author":"Murphy","year":"2018","journal-title":"JAMA Oncol"},{"key":"R37-20250928","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1245\/s10434-017-6281-9","article-title":"Neoadjuvant therapy versus upfront resection for pancreatic cancer: the actual spectrum and clinical burden of postoperative complications.","volume":"25","author":"Marchegiani","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"R38-20250928","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12885-021-07877-7","article-title":"A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma.","volume":"21","author":"Paiella","year":"2021","journal-title":"BMC Cancer"},{"key":"R39-20250928","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2\/3 trial.","volume":"268","author":"Jang","year":"2018","journal-title":"Ann Surg"},{"key":"R40-20250928","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12957-019-1687-4","article-title":"Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study.","volume":"17","author":"Endo","year":"2019","journal-title":"World J Surg Oncol"},{"key":"R41-20250928","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2013.50.7657","article-title":"Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.","volume":"32","author":"Valle","year":"2014","journal-title":"J Clin Oncol"},{"key":"R42-20250928","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/COC.0000000000000688","article-title":"Neoadjuvant phase II trial of chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer.","volume":"43","author":"Thanikachalam","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"R43-20250928","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s12957-024-03609-w","article-title":"Efficacy and safety of neoadjuvant S-1-based chemoradiotherapy in resectable and borderline-resectable pancreatic cancer: a long-term follow-up study.","volume":"22","author":"Shimane","year":"2024","journal-title":"World J Surg Oncol"},{"key":"R44-20250928","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1007\/s10238-023-01112-2","article-title":"The benefits of neoadjuvant therapy for patients with resectable pancreatic cancer: an updated systematic review and meta-analysis.","volume":"23","author":"Yang","year":"2023","journal-title":"Clin Exp Med"},{"key":"R45-20250928","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial.","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"key":"R46-20250928","doi-asserted-by":"crossref","first-page":"979390","DOI":"10.3389\/fonc.2022.979390","article-title":"Is neoadjuvant chemoradiotherapy for pancreatic cancer beneficial: a systematic review and meta-analysis.","volume":"12","author":"Luo","year":"2022","journal-title":"Front Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:03:40Z","timestamp":1759046620000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":46,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044570","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"2025-03-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}